Connecting Psychiatry - Expert community for all mental health professionals

Aricept (donepezil) Wins Indication for Severe Alzheimer's

(PSYCHIATRIC TIMES) - MedPage Today Action Points

ROCKVILLE, Md., Oct. 13 -- Aricept (donepezil), a cholinesterase inhibitor on the market for mild to moderate Alzheimer's disease, today became the first of its class to win FDA approval for severe disease.

The FDA action made Aricept the only drug approved to treat all stages of Alzheimer's.

The FDA decision was based on efficacy demonstrated in two randomized, placebo-controlled 24-week trials in Sweden and Japan. The trials enrolled more than 500 patients with severe Alzheimer's dementia.

Both trials evaluated Aricept's efficacy with standard measures that assessed cognitive function including memory, language, orientations, and attention as well as overall functioning. The patients randomized to Aricept had better scores than patients in the placebo arms of both studies.

For full article, please visit:

Views: 8


You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds

psychiatryRounds Social Media


CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2021   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service